Mark Low, Managing Director of the Global Cardiovascular Innovation Center (GCIC) and the NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic, comes to these roles with a career of building successful programs to introduce new technologies to address new market opportunities in healthcare. He has managed all facets of product and market development spanning diagnostic and interventional cardiology, interventional radiology and neuroradiology, stroke treatment, image-guided surgery, drug delivery and oncology. He has served on the senior management team of TomTec Imaging Systems, Image Guided Technologies, EKOS Corporation, and Sonus Pharmaceuticals. Prior to concentrating his focus on start-up ventures and early stage market development, Mr. Low held trailblazing positions in marketing and business development for Hewlett-Packard’s Medical Products Group. Specializing in cardiovascular ultrasound, Mr. Low managed high performance cardiac diagnostic systems, introducing 3D and stress echocardiography, and catheter-based intravascular ultrasound, among other applications. In conjunction with these programs Mr. Low managed strategic relationships with various corporate partners, investors, universities, inventors, clinical investigators and manufacturers. Mr. Low received a B.A. degree in Natural Science from Johns Hopkins University, an M.S. degree in Physiology from the Medical College of Wisconsin, and an M.S. degree in Technical Communication from Rensselaer Polytechnic Institute.
Michael serves as a primary research and analytical resource for Innovations and its partners with a focus on market assessment of new medical technologies. Prior to joining the Clinic, he spent more than 11 years at Health Research International, an independent medical market research and consulting firm, most recently as Vice President. This experience entailed working closely with a broad range of medical technology firms from local start-ups to multinationals. Michael earned a BA in business administration (cum laude, Marketing major) from the Richard T. Farmer School of Business at Miami University.
Marwane has been a leader in the field of medical devices for over fourteen (14) years and has extensive experience in product development and commercialization of Class II and Class III devices. Product expertise has been in percutaneous therapies such as electrophysiology, structural heart, cardiovascular and endovascular devices, in addition to product commercialization of orthopedic implants. Through his engineering and business backgrounds, Marwane is experienced in leading both traditional and virtual R&D teams throughout the entire development life-cycle including 510k and PMA regulatory tracks. Marwane has held various technical/engineering, managerial, and executive management positions in companies such as Boston Scientific, Microvena, ev3, CryoCath Technologies, Bavaria Medical Technologies, Vascular NanoTransfer and OligoMedic. Currently Marwane holds eight (8) patents in medical devices and more than fourteen (14) others as patent applications. Marwane holds a Bachelor’s and Master’s degree in Mechanical Engineering from the University of Minnesota and an MBA in Finance from McGill University.
Veronika’s function serves as liaison and administrative, technical, and operational resource for the Global Cardiovascular Innovation Center team. She has an extensive background providing support to senior-level Executives and world class service to all valued customers.
Kelly B. Emerton, PhD, joins the GCIC team as Sr. Director of Product Development, lending her medical device industry experience towards the GCIC mission of developing and commercializing cardiovascular technology. Prior to joining the GCIC team , she spent 6+ years across Medtronic business units (Spine and Endovascular Therapy divisions) leading multiple major development programs with cross-functional execution. Her background includes US and outside US regulatory approvals for Class III implantable and combination-product devices for orthopedic and endovascular therapy indications. During her Endovascular Therapy tenure, she was responsible for leading multiple pipeline programs within the thoracic aortic product portfolio. Kelly received a B.S.E degree in Biomedical Engineering from Michigan Technological University, and a Masters and Doctorate in Biomedical Engineering from City College at the City University of New York.
Laura is responsible for the overall management of the Global Cardiovascular Innovation Center, a 50,000 square foot facility that houses the GCIC’s incubator/accelerator program. Her responsibilities include facilities management and service, lease agreements, and financial activities. Her responsibilities also include the management of our Preclinical Program where she serves as a liaison between all levels of management, various departments, and our vendors.
Suguna Rachakonda has over 11 years of experience in small molecule drug discovery in various therapeutic areas. She spent a year at United Therapeutics and 10 years at Pharmasset Inc. (acquired by Gilead Sciences). Suguna was a key contributor to the discovery and development of multiple clinical candidates for antiviral diseases including the recently marketed Hepatitis C drug Sovaldi®. She was responsible for leading multiple outsourcing project development teams. Suguna is an inventor on 10 patents. Prior to joining CCI, Suguna was Director of Technology Commercialization at Kent State University leading all aspects of innovation management and commercialization.
Suguna received a Ph.D. in Organic Chemistry from University of Hyderabad, India. Subsequently she was a post-doctoral fellow at Tulane University. She received an MBA in Finance from Stern School of Business, New York University.